amikacin has been researched along with Bacterial Infections, Gram-Negative in 111 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.90) | 18.7374 |
| 1990's | 37 (33.33) | 18.2507 |
| 2000's | 32 (28.83) | 29.6817 |
| 2010's | 37 (33.33) | 24.3611 |
| 2020's | 4 (3.60) | 2.80 |
| Authors | Studies |
|---|---|
| Avison, MB; Okazaki, A | 1 |
| Baudry, PJ; DeCorby, M; Hoban, DJ; Johnson, J; Karlowsky, JA; Lagacé-Wiens, P; Laing, N; McCracken, M; Mulvey, MR; Nichol, KA; Tailor, F; Vashisht, R; Walkty, A; Weshnoweski, B; Wierzbowski, A; Zhanel, GG | 1 |
| Amsler, KM; Bush, K; Davies, TA; Jacobs, MR; Shang, W | 1 |
| Amicosante, G; De Luca, F; Luzzaro, F; Migliavacca, R; Mugnaioli, C; Pagani, L; Perilli, M; Pini, B; Pollini, S; Rossolini, GM; Spalla, M; Toniolo, A | 1 |
| Badal, RE; Bouchillon, SK; Hawser, SP; Hoban, DJ; Hsueh, PR; Paterson, DL | 1 |
| Alder, J; Bassetti, M; Boateng, F; Cao, B; Chastre, J; Corkery, K; Dhand, R; Kaye, KS; Lawatscheck, R; McLeroth, P; Nicolau, DP; Niederman, MS; Wang, C; Wood, GC; Wunderink, RG | 1 |
| Huh, HJ; Kang, JM; Kim, YJ; Koo, HH; Lee, JW; Lee, NH; Lee, NY; Sung, KW; Yoo, KH | 1 |
| Du, B; Huang, HB; Qin, JP; Xu, Y; Zhou, H; Zhu, Y | 1 |
| Bragantini, D; Carrara, E; Cattaneo, P; Chiamenti, M; Ellis, S; Franceschi, F; Giske, CG; Lodise, T; Menchinelli, G; Piddock, LJV; Righi, E; Sanguinetti, M; Savoldi, A; Scudeller, L; Tacconelli, E | 1 |
| Abbassi, MM; Awdallah, FF; Hassan, NA; Sabry, NA | 1 |
| Cikánková, T; Hartinger, J; Šíma, M; Slanař, O | 1 |
| Bora, F; Ersoy, F; Yılmaz, F | 1 |
| Alfonso, EC; Gibbons, A; Miller, D; OʼBrien, TP; Palioura, S; Spierer, O | 1 |
| Guimbellot, JS; Poore, TS; Virella-Lowell, I | 1 |
| Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
| Allegaert, K; De Cock, P; Healy, DP; Kagan, RJ; Liu, X; Renard, M; Sherwin, CMT; Smits, A; Wang, Y; Wead, S | 1 |
| Chung, KM; Hwang, JH; Lee, CS; Lee, TH; Lee, WK; Shin, MK; Woo, HR | 1 |
| Aires, CAM; Asensi, MD; Carvalho-Assef, APD; Conceição-Neto, OC; da Silva, IR; de Oliveira Santos, IC; Ferreira Pereira, N; Moreno Senna, JP; Rocha-de-Souza, CM | 1 |
| Chen, Y; Cui, Y; Guo, P; Guo, X; Shao, S | 1 |
| Ahmadi, A; Mahmoudi, L; Mohammadpour, AH; Mojtahedzadeh, M; Niknam, R | 1 |
| Heath, PT; Kent, A; Sharland, M; Turner, MA | 1 |
| Bouadma, L; Chemam, S; de Montmollin, E; Gault, N; Mariotte, E; Massias, L; Mourvillier, B; Papy, E; Sonneville, R; Tubach, F; Wolff, M | 1 |
| Alba, L; Behta, M; Clock, SA; Della-Latta, P; Furuya, EY; Jenkins, SG; Jia, H; Kubin, CJ; Oliveira, AP; Patel, SJ; Rhee, K; Saiman, L; Schuetz, AN; Weisenberg, SA; Whittier, S; Zhou, JJ | 1 |
| Abuan, T; Flamm, RK; Montgomery, AB; Rhomberg, PR; Walters, KA | 1 |
| Bueno, MF; Camargo, CH; Ferreira, AM; Francisco, GR; Gallo, JF; Garcia, Dde O; Javaroni, E; Reis, BA | 1 |
| Armand-Lefèvre, L; Burdet, C; Couffignal, C; Foucrier, A; Laouénan, C; Massias, L; Mentré, F; Pajot, O; Wolff, M | 1 |
| Armand-Lefevre, L; Burdet, C; Couffignal, C; Da Silva, D; Foucrier, A; Laouénan, C; Lasocki, S; Massias, L; Mentec, H; Mentré, F; Pajot, O; Wolff, M | 1 |
| Beaudoin, T; LiPuma, JJ; Tom, SK; Waters, V; Yau, YC | 1 |
| Badal, RE; Hackel, MA; Lob, SH; Sahm, DF | 1 |
| Bouadma, L; de Montmollin, E; Gélisse, E; Mourvillier, B; Neuville, M; Sonneville, R; Timsit, JF | 1 |
| Boulain, T; Danker, W; Dimopoulos, G; Francois, B; Garot, D; Ischaki, E; Ivanyi, Z; János, G; Kollef, MH; Koura, F; Montgomery, AB; Ricard, JD; Roux, D; Rozgonyi, Z; Torres, A; Zakynthinos, E | 1 |
| Chandra, A; Desai, C; Dhar, P; Dharap, S; Goel, A; Gupta, R; Hardikar, JV; Kapoor, VK; Kochhar, P; Mathur, AK; Modi, P; Narwaria, M; Ramesh, H; Ramesh, MK; Sastry, RA; Schou, M; Shah, S; Somasundaram, S; Sreevathsa, MR; Sudheer, OV; Varshney, S; Virk, S | 1 |
| Azim, A; Baronia, AK; Dwivedi, M; Dwivedi, UN; Mishra, A; Prasad, A; Prasad, KN; Singh, RK | 1 |
| Agarwala, S; Bakhshi, S; Gupta, A; Pandey, RM; Swaroop, C | 1 |
| Sweileh, WM | 1 |
| Chastre, J; Clavel, M; Corkery, K; Gribben, D; Guntupalli, K; Johannigman, J; Kennedy, JI; Luyt, CE; Wood, C | 1 |
| Ali-Dinar, T; Colin, AA | 1 |
| Aysev, D; Doğu, F; Erol Cipe, F; Ikincioğulları, A; Sucuoğlu, D | 1 |
| Chastre, J; Corkery, K; Eldon, MA; Gribben, D; Luyt, CE; Stass, H | 1 |
| Hsieh, CJ; Hsueh, PR; Hwang, KP; Kuo, KC | 1 |
| Ales, M; Bove, F; Cudillo, L; Cupelli, L; Dentamaro, T; Fabritiis, Pd; Falco, S; Giovannini, M; Mirabile, M; Niscola, P; Picardi, A; Scaramucci, L; Spagnoli, A; Tendas, A | 1 |
| Dong, M; He, J; Meng, X; Sun, M; Wang, DI; Yang, C; Zhu, L | 1 |
| Akers, KS; Chung, KK; Cota, JM; Frei, CR; Mende, K; Murray, CK | 1 |
| Chastre, J; Corkery, K; Fink, JB; García, MS; Luyt, CE; Niederman, MS | 1 |
| Koh, JW; Park, JH; Song, NH | 1 |
| Falagas, ME; Georgantzi, GG; Karageorgopoulos, DE; Rafailidis, PI; Sun, C; Wang, R | 1 |
| Aboussad, A; Chabaa, L; Elidrissi, NS; Issaoui, S; Maoulainine, FM; Sorra, N | 1 |
| Goyal, S; Warner, DB | 1 |
| Hewer, SL | 1 |
| Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Ni, Y; Tang, HJ; Toh, HS; Wang, JH; Xu, Y; Yu, KW | 1 |
| Choi, JY; Kim, JM; Ku, NS; Lee, K; Yong, D | 1 |
| He, HX; Hu, WL; Zhong, SZ | 1 |
| Belmont, A; Ibarra, J; Limón, G; Martínez, C; Poblano, A; Sosa, J; Vargas, AM | 1 |
| Chacko, AG; Chacko, G; Shankar, A | 1 |
| Huff, D; KuKanich, B; Papich, M; Stoskopf, M | 1 |
| Chiodo, F; Frank, G; Manfredi, R; Sabbatani, S | 1 |
| Castagnola, E; Caviglia, I; Giona, F; Girmenia, C; Haupt, R; Micozzi, A; Parodi, S; Testi, AM | 1 |
| Archambaud, M; Chabanon, G; Conil, JM; Cougot, P; Decun, JF; Georges, B; Houin, G; Saivin, S; Seguin, T; Virenque, C | 1 |
| Chong, Y; Ha, GY; Jeong, SH; Lee, K; Lim, HS; Park, KH; Shin, JH; Yong, D | 1 |
| Chayani, N; Mahapatra, A; Mallick, B; Panda, R; Poddar, N; Roy, D; Sarangi, G | 1 |
| Alexaki, P; Alivizatos, AS; Athanasiou, AE; Chalkiopoulou, I; Christakis, GB; Zarkadis, IK | 1 |
| Cunha, BA | 1 |
| Alp, E; Aygen, B; Metan, G; Sumerkan, B | 1 |
| Akyüz, C; Gür, D; Kirazli, S; Sayinalp, N; Tavil, B; Uckan, D | 1 |
| Kiatjaroensin, SA; Panomvana, D; Phiboonbanakit, D | 1 |
| Guevara, A; Guevara, E; Guevara, M; Medina, L; Oliveros, M; Salomón, M | 1 |
| Kim, MK; Lee, JH; Lee, JL; Lee, SM; Wee, WR | 1 |
| Erdeljić, V; Francetić, I; Huić, M; Kalenić, S; Likić, R; Makar-Ausperger, K; Mercep, I; Simić, P; Tripković, V | 1 |
| García, DC; Kaufman, S; Piñeiro, S; Sordelli, DO; Woloj, GM | 1 |
| Kahr, A; Michéa-Hamzehpour, M; Pechère, JC | 1 |
| Cogoluenhes, V; Confesson, MA; Courpron, P; Druguet, M; Grillot, M; Jelliffe, RW; Maire, PH; Pivot, C | 1 |
| Cieslak, TJ; Raszka, WV | 1 |
| Ahrne, H; Holmen, C; Lausen, I; Maller, R; Nilsson, LE; Smedjegård, J | 1 |
| Herchuelz, A; Siska, G; Vanhaeverbeek, M | 1 |
| Douchamps, J; Herchuelz, A; Siska, G; Vanhaeverbeek, M | 1 |
| Marik, PE | 1 |
| Blaise, D; Cordonnier, C; Espinouse, D; Herbrecht, R; Leblond, V; Minozzi, C; Sadoun, A; Sauvage, C | 1 |
| Colardyn, F | 1 |
| Covi, M; Velluti, G | 1 |
| Esparza-Ahumada, S; Morfin-Otero, R; Rodriguez-Noriega, E | 1 |
| Beaucaire, G | 1 |
| Carbon, C | 1 |
| López, MM; Martín, C; Merino, J; Navarro, V; Roig, PP; Sánchez, B; Zorraquino, A | 1 |
| Avilés, A; Díaz-Maqueo, JC; García, EL; Guzmán, R; Talavera, A | 1 |
| Bell-Dixon, C; Itokazu, GS; Kahan, FM; Quinn, JP; Weinstein, RA | 1 |
| Abu-Aisha, H; al-Zeer, AH; Dahmash, NS; Fayed, DF; Huraib, SO; Shibl, AM | 1 |
| Ardanuy, C; Carratalá, J; Fernández-Sevilla, A; González-Barca, E; Grañena, A; Sanchez, A | 1 |
| Castañeda-Hernández, G; Lugo, G | 1 |
| Calvo, MV; Dominguez-Gil, A; Fernández de Gatta, MM; Lanao, JM; Mendez, ME; Romano, S | 1 |
| Donazzan, M; Ferri, F; Rose, C; Tellion, C | 1 |
| Cuccia, A; O'Riordan, TG; Palmer, LB; Simon, SR; Smaldone, GC | 1 |
| Behre, G; Hiddemann, W; Link, H; Maschmeyer, G; Meyer, P; Paaz, U; Wilhelm, M | 1 |
| Krcmery, V; Krupova, Y; Mateicka, F; Novotny, J; Sabo, A | 1 |
| Brouqui, P; Le Pocher, H; Raoult, D | 1 |
| Wang, CK; Yang, CH | 1 |
| Zafar, A | 1 |
| Christodoulou, C; Dellagrammaticas, HD; Kapetanakis, J; Kourakis, G; Megaloyanni, E; Papadimitriou, M | 1 |
| Fabbri, A; Fanci, R; Leoni, F; Longo, G; Martinez, RL; Paci, C; Pecile, P | 1 |
| Aznar, E; Climent, MA; Máiquez, J; Palau, J; Picón, I | 1 |
| Adinolfi, LE; Andreana, A; Ragone, E; Sarnataro, G; Tripodi, MF; Utili, R | 1 |
| Boffa, ML; De Blasi, D; Mastrullo, L; Miraglia, E; Orlando, R; Zorzato, G | 1 |
| Ajarim, DS; al Mohareb, F; al Momen, AK; Harakati, MS; Santhosh-Kumar, CR; Zeitany, RG | 1 |
| Maes, P; Vanhoof, R | 1 |
| Friedland, IR; Funk, E; Khoosal, M; Klugman, KP | 1 |
| Brown, AC; Huggins, ML; Iliadis, A | 1 |
| Akalin, HE; Gür, D; Kocagöz, T | 1 |
| Conrad, SA; King, JW; Todd, JR; White, MC | 1 |
| Cipolle, RJ; Kohls, PR; Rotschafer, JC; Strate, RG; Zaske, DE | 1 |
| Kobilski, S; Lipman, J; Marik, PE; Scribante, J | 1 |
| Minneci, M; Nicoletti, G; Salmeri, M; Toscano, MA | 1 |
| Kua, LT; Limson, BM; Litam, P; Navarro-Almario, E; Que, E | 1 |
8 review(s) available for amikacin and Bacterial Infections, Gram-Negative
| Article | Year |
|---|---|
Amikacin nebulization for the adjunctive therapy of gram-negative pneumonia in mechanically ventilated patients: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Critical Care; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Length of Stay; Middle Aged; Nebulizers and Vaporizers; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Respiration, Artificial; Treatment Outcome | 2021 |
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Polymyxins; Rifampin; Tazobactam; Tobramycin | 2021 |
Roseomonas mucosa infective endocarditis in patient with systemic lupus erythematosus: case report and review of literature.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Bacteremia; Endocarditis; Endocarditis, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Lupus Erythematosus, Systemic; Methylobacteriaceae; Piperacillin, Tazobactam Drug Combination | 2019 |
Aminoglycoside toxicity in neonates: something to worry about?
Topics: Amikacin; Aminoglycosides; Animals; Anti-Infective Agents; Drug-Related Side Effects and Adverse Reactions; Ear, Inner; Gentamicins; Gram-Negative Bacterial Infections; Humans; Infant, Newborn; Kidney | 2014 |
Susceptibility of Gram-negative bacteria to isepamicin: a systematic review.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Child; Child, Preschool; Databases, Bibliographic; Drug Administration Schedule; Drug Resistance, Bacterial; Gentamicins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Microbial Sensitivity Tests | 2012 |
Inhaled antibiotics in cystic fibrosis: what's new?
Topics: Administration, Inhalation; Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Child; Child, Preschool; Ciprofloxacin; Clinical Trials, Phase III as Topic; Cystic Fibrosis; Female; Follow-Up Studies; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Incidence; Infant; Male; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Survival Rate; Tobramycin; Treatment Outcome | 2012 |
Capnocytophaga spp. brain abscess in an immunocompetent host: problems in antimicrobial chemotherapy and literature review.
Topics: Adult; Amikacin; Animals; Anti-Bacterial Agents; Bites and Stings; Brain Abscess; Capnocytophaga; Cats; Clindamycin; Diagnosis, Differential; Fluconazole; Gram-Negative Bacterial Infections; Humans; Imipenem; Male | 2004 |
New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited.
Topics: Amikacin; Cell Membrane; Colistin; Doxycycline; Drug Resistance, Microbial; Gram-Negative Bacterial Infections; Humans; Methicillin Resistance; Minocycline; Nitrofurantoin; Polymyxin B; Staphylococcal Infections; Urinary Tract Infections | 2006 |
29 trial(s) available for amikacin and Bacterial Infections, Gram-Negative
| Article | Year |
|---|---|
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Skin Diseases, Bacterial; Staphylococcus | 2008 |
Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.
Topics: Administration, Inhalation; Administration, Intravenous; Adult; Aged; Amikacin; Anti-Bacterial Agents; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Gram-Negative Bacterial Infections; Hospitals; Humans; Male; Middle Aged; Placebos; Pneumonia, Ventilator-Associated; Prospective Studies; Standard of Care; Survival Analysis; Treatment Outcome; Young Adult | 2020 |
Nebulized Versus IV Amikacin as Adjunctive Antibiotic for Hospital and Ventilator-Acquired Pneumonia Postcardiac Surgeries: A Randomized Controlled Trial.
Topics: Administration, Inhalation; Adult; Amikacin; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Multiple; Female; Gram-Negative Bacterial Infections; Heart Diseases; Humans; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Postoperative Complications; Prospective Studies; Treatment Outcome | 2018 |
Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
Topics: Adult; Amikacin; Anti-Bacterial Agents; APACHE; Creatinine; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gram-Negative Bacterial Infections; Hemodynamics; Humans; Intensive Care Units; Male; Middle Aged; Models, Biological; Sepsis; Severity of Illness Index; Tissue Distribution | 2013 |
Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Critical Illness; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Pneumonia, Ventilator-Associated | 2015 |
A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial.
Topics: Administration, Inhalation; Adult; Aged; Amikacin; Anti-Bacterial Agents; APACHE; Chemotherapy, Adjuvant; Double-Blind Method; Female; Fosfomycin; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Pneumonia, Ventilator-Associated; Treatment Outcome | 2017 |
Cefoperazone-sulbactam for treatment of intra-abdominal infections: results from a randomized, parallel group study in India.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Cefoperazone; Ceftazidime; Child; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; India; Male; Metronidazole; Middle Aged; Peritonitis; Sulbactam; Treatment Failure; Treatment Outcome | 2008 |
Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
Topics: Administration, Oral; Adolescent; Ambulatory Care; Amikacin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Ceftriaxone; Child; Child, Preschool; Drug Therapy, Combination; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Injections, Intravenous; Male; Neoplasms; Neutropenia; Ofloxacin; Treatment Outcome | 2009 |
A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gentamicins; Gram-Negative Bacterial Infections; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Young Adult | 2009 |
Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure.
Topics: Acute Kidney Injury; Aerosols; Aged; Amikacin; Anti-Bacterial Agents; Area Under Curve; Critical Illness; Drug Delivery Systems; Female; Follow-Up Studies; Gram-Negative Bacterial Infections; Hemodiafiltration; Humans; Male; Middle Aged; Pneumonia, Bacterial; Respiration, Artificial; Tissue Distribution | 2011 |
BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia.
Topics: Aerosols; Amikacin; Anti-Bacterial Agents; Body Fluids; Double-Blind Method; Female; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Respiration, Artificial; Trachea | 2012 |
Treatment of chronic bacterial prostatitis with amikacin through anal submucosal injection.
Topics: Adult; Amikacin; Anal Canal; Anti-Bacterial Agents; Biopsy; Gram-Negative Bacterial Infections; Humans; Injections; Male; Middle Aged; Mucous Membrane; Prostatitis; Treatment Outcome | 2002 |
Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Area Under Curve; Cefepime; Cephalosporins; Critical Illness; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Time Factors; Treatment Outcome | 2005 |
Correlation of the pharmacokinetic parameters of amikacin and ceftazidime.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Regression Analysis | 2007 |
Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. Scandinavian Amikacin Once Daily Study Group.
Topics: Amikacin; Drug Administration Schedule; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Hearing; Humans; Kidney; Male; Middle Aged | 1993 |
Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe gram-negative infections in the elderly.
Topics: Aged; Amikacin; Drug Administration Schedule; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged | 1993 |
Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bone Marrow Transplantation; Ceftriaxone; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; Gentamicins; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Superinfection | 1995 |
The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection.
Topics: Acute Disease; Amikacin; Anti-Bacterial Agents; Bronchitis; Ceftazidime; Cross Infection; Drug Administration Schedule; Drug Therapy, Combination; Female; Gentamicins; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Pneumonia, Bacterial; Respiratory Tract Infections; Retrospective Studies | 1995 |
Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of acute lower respiratory tract infections caused by gram-negative organisms.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bronchitis; Drug Administration Schedule; Drug Therapy, Combination; Female; Gentamicins; Gram-Negative Bacterial Infections; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections | 1995 |
Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Drug Administration Schedule; Escherichia coli Infections; Female; Gentamicins; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Proteus Infections; Proteus mirabilis; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Staphylococcus aureus | 1995 |
Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia.
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Cross Infection; Drug Therapy, Combination; Female; Gentamicins; Gram-Negative Bacterial Infections; Humans; Lactams; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies | 1995 |
Overview of the efficacy of isepamicin in the adult core clinical trial programme.
Topics: Abdomen; Adult; Aged; Amikacin; Anti-Bacterial Agents; Bacteremia; Drug Administration Schedule; Female; Gentamicins; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Prospective Studies; Respiratory Tract Infections; Skin Diseases, Bacterial; Urinary Tract Infections | 1995 |
Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Agranulocytosis; Amikacin; Antineoplastic Agents; Ceftazidime; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Mycoses; Prospective Studies; Superinfection | 1996 |
Aerosolized antibiotics in mechanically ventilated patients: delivery and response.
Topics: Adult; Aerosols; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Case-Control Studies; Chronic Disease; Colony Count, Microbial; Cross Infection; Cytokines; Gentamicins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intercellular Adhesion Molecule-1; Male; Nebulizers and Vaporizers; Prospective Studies; Respiration, Artificial; Respiratory Insufficiency; Respiratory Tract Infections; Sputum; Trachea; Tracheostomy | 1998 |
Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Bacteremia; Bacterial Infections; Ceftazidime; Cephalosporins; Drug Therapy, Combination; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Male; Meropenem; Middle Aged; Neutropenia; Thienamycins | 1998 |
Management of fever in neutropenic patients with acute leukemia: current role of ceftazidime plus amikacin as empiric therapy.
Topics: Acute Disease; Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Drug Therapy, Combination; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Leukemia, Myeloid; Male; Middle Aged; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2000 |
APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics.
Topics: Amikacin; Bayes Theorem; Body Weight; Drug Administration Schedule; Drug Costs; Drug Monitoring; France; Gram-Negative Bacterial Infections; Humans; Software Validation | 1992 |
A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients.
Topics: Adolescent; Adult; Amikacin; Creatinine; Critical Care; Female; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Kidney Diseases; Male; Middle Aged; Prospective Studies | 1991 |
Ceftazidime versus a combination of amikacin and ticarcillin in the treatment of severe infections.
Topics: Adult; Aged; Amikacin; Ceftazidime; Cross Infection; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Ticarcillin | 1988 |
74 other study(ies) available for amikacin and Bacterial Infections, Gram-Negative
| Article | Year |
|---|---|
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Butirosin Sulfate; Drug Resistance, Multiple, Bacterial; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Kanamycin; Kanamycin Kinase; Microbial Sensitivity Tests; Mutation; Neomycin; Stenotrophomonas maltophilia | 2007 |
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; Canada; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance | 2008 |
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
Topics: Base Sequence; beta-Lactam Resistance; beta-Lactamases; Data Collection; DNA Primers; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Integrons; Italy; Molecular Epidemiology; Molecular Sequence Data | 2008 |
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; China; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Imipenem; India; Klebsiella; Quinolones; Thailand | 2009 |
Cefepime Versus Cefepime Plus Amikacin as an Initial Antibiotic Choice for Pediatric Cancer Patients With Febrile Neutropenia in an Era of Increasing Cefepime Resistance.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Bacteremia; Cefepime; Chemotherapy-Induced Febrile Neutropenia; Child; Child, Preschool; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Male; Neoplasms; Retrospective Studies; Treatment Outcome | 2020 |
Estimation of once-daily amikacin dose in critically ill adults.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Critical Illness; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged | 2018 |
Peritoneal Dialysis Related Peritonitis by Sphingomonas Paucimobilis.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Female; Gram-Negative Bacterial Infections; Humans; Middle Aged; Peritoneal Dialysis; Peritonitis; Sphingomonas; Treatment Outcome | 2018 |
Clinical Features, Antibiotic Susceptibility Profile, and Outcomes of Infectious Keratitis Caused by Stenotrophomonas maltophilia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Corneal Ulcer; Eye Infections, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Polymyxin B; Retrospective Studies; Risk Factors; Stenotrophomonas maltophilia; Tobramycin; Trimethoprim, Sulfamethoxazole Drug Combination; Young Adult | 2018 |
Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis.
Topics: Amikacin; Anti-Bacterial Agents; Child; Ciprofloxacin; Clindamycin; Cystic Fibrosis; Gram-Negative Bacterial Infections; Humans; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Rhodospirillaceae; Stenotrophomonas maltophilia; Virulence | 2018 |
Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Load; beta-Lactamase Inhibitors; Cephalosporins; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Models, Theoretical; Tazobactam | 2018 |
Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Burns; Child; Child, Preschool; Female; Gram-Negative Bacterial Infections; Humans; Infant; Male; Neoplasms; Retrospective Studies | 2019 |
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Proteins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Methyltransferases; Republic of Korea; RNA, Ribosomal, 16S | 2018 |
Distribution of Clinical NDM-1-Producing Gram-Negative Bacteria in Brazil.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Brazil; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Tertiary Care Centers | 2019 |
Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Body Mass Index; Body Weight; Critical Illness; Dose-Response Relationship, Drug; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Injections; Intensive Care Units; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Risk Factors | 2014 |
Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units.
Topics: Acinetobacter Infections; Adolescent; Age Factors; Aged; Amikacin; Anti-Bacterial Agents; Case-Control Studies; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Immunocompromised Host; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Liver Diseases; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Time Factors | 2014 |
Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens.
Topics: Acinetobacter baumannii; Amikacin; Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Synergism; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Respiratory Tract Infections | 2014 |
Microbiological characterization of Delftia acidovorans clinical isolates from patients in an intensive care unit in Brazil.
Topics: Amikacin; Brazil; Delftia acidovorans; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Microbial Sensitivity Tests; Molecular Typing; RNA, Ribosomal, 16S; Trimethoprim, Sulfamethoxazole Drug Combination | 2014 |
Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bacterial Load; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Treatment Outcome | 2015 |
Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients.
Topics: Achromobacter; Amikacin; Anti-Bacterial Agents; Aztreonam; Biofilms; Colistin; Cystic Fibrosis; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Plankton; Tobramycin | 2016 |
Epidemiology and Antimicrobial Susceptibility of Gram-Negative Pathogens Causing Intra-abdominal Infections in Pediatric Patients in Europe-SMART 2011-2014.
Topics: Adolescent; Amikacin; Appendicitis; Child; Child, Preschool; Community-Acquired Infections; Cross Infection; Cross-Sectional Studies; Drug Resistance, Microbial; Drug Resistance, Multiple, Bacterial; Europe; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Infant; Male; Microbial Sensitivity Tests | 2017 |
Extracorporeal membrane oxygenation (ECMO) does not impact on amikacin pharmacokinetics: a case-control study.
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Case-Control Studies; Critical Illness; Extracorporeal Membrane Oxygenation; Female; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Male; Middle Aged; Treatment Outcome | 2016 |
Aeromonas caviae septicemia in immunocompetent gastrointestinal carriers.
Topics: Aeromonas; Amikacin; Anti-Bacterial Agents; Bacteremia; Carrier State; Community-Acquired Infections; Digestive System; Feces; Gram-Negative Bacterial Infections; Humans; Immunocompetence; India | 2008 |
Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia.
Topics: Aerosols; Amikacin; Anti-Bacterial Agents; Cross Infection; Gram-Negative Bacterial Infections; Humans; Intubation; Lung; Respiration, Artificial | 2009 |
Aerosolized amikacin and oral clarithromycin to eradicate Mycobacterium abscessus in a patient with cystic fibrosis: an 8-year follow-up.
Topics: Administration, Oral; Adult; Amikacin; Anti-Bacterial Agents; Clarithromycin; Cystic Fibrosis; Drug Therapy, Combination; Female; Forced Expiratory Volume; Gram-Negative Bacterial Infections; Humans; Mycobacterium; Mycobacterium Infections; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Stenotrophomonas maltophilia | 2010 |
Asymptomatic catheter related Rhizobium radiobacter infection in a haploidentical hemapoetic stem cell recipient.
Topics: Agrobacterium tumefaciens; Amikacin; Anti-Bacterial Agents; Blood; Catheter-Related Infections; Catheterization, Central Venous; Catheters; Cefepime; Cephalosporins; Cross Infection; Female; Gram-Negative Bacterial Infections; Humans; Immunocompromised Host; Infant; Severe Combined Immunodeficiency; Stem Cell Transplantation | 2010 |
Facial cellulitis because of Aggregatibacter (Actinobacillus) actinomycetemcomitans and Capnocytophaga species in an immunocompetent patient.
Topics: Actinobacillus Infections; Administration, Oral; Adolescent; Aggregatibacter actinomycetemcomitans; Amikacin; Capnocytophaga; Cellulitis; Clarithromycin; Face; Female; Gram-Negative Bacterial Infections; Humans | 2011 |
Controversies on antibiotic lock technique duration: experience with a 3-day course for hematological patients.
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Catheter-Related Infections; Catheters, Indwelling; Gram-Negative Bacterial Infections; Humans; Staphylococcal Infections; Staphylococcus epidermidis; Staphylococcus haemolyticus; Teicoplanin; Time Factors; Vancomycin | 2011 |
Antimicrobial susceptibility patterns of clinical isolates of gram-negative bacteria obtained from intensive care units in a tertiary hospital in Beijing, China.
Topics: Amikacin; Anti-Bacterial Agents; China; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Imipenem; Intensive Care Units; Microbial Sensitivity Tests | 2011 |
Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration.
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Burns; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hemofiltration; Humans; Male; Middle Aged; Retrospective Studies | 2011 |
Achromobacter xylosoxidans keratitis after contact lens usage.
Topics: Achromobacter denitrificans; Adult; Amikacin; Anti-Bacterial Agents; Ceftazidime; Contact Lenses, Extended-Wear; Female; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; Keratitis; Tobramycin | 2012 |
[Neonatal infection with Stenotrophomonas maltophilia (2 case studies)].
Topics: Amikacin; Anti-Bacterial Agents; Brain Abscess; Chloramphenicol; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Echoencephalography; Empyema, Subdural; Fatal Outcome; Female; Gram-Negative Bacterial Infections; Humans; Infant, Newborn; Intensive Care Units, Neonatal; Male; Meningitis, Bacterial; Microbial Sensitivity Tests; Pneumonia, Bacterial; Sepsis; Stenotrophomonas maltophilia; Thiamphenicol; Tomography, X-Ray Computed | 2012 |
Roseomonas keratitis after remote penetrating keratoplasty.
Topics: Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Corneal Perforation; Corneal Ulcer; Eye Infections, Bacterial; Female; Fuchs' Endothelial Dystrophy; Gram-Negative Bacterial Infections; Humans; Keratoplasty, Penetrating; Methylobacteriaceae; Surgical Wound Infection; Tobramycin; Visual Acuity | 2013 |
Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Topics: Amikacin; Anti-Bacterial Agents; Asia; Australasia; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Drug Resistance, Bacterial; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Prospective Studies; Urinary Tract Infections | 2012 |
Correlations between aminoglycoside consumption and aminoglycoside resistance in Gram-negative bacteria at a tertiary-care hospital in South Korea from 2001 to 2011.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Utilization; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Republic of Korea; Tertiary Care Centers; Tobramycin | 2013 |
Amikacin alters auditory brainstem conduction time in newborns.
Topics: Amikacin; Anti-Bacterial Agents; Evoked Potentials, Auditory, Brain Stem; Female; Gestational Age; Gram-Negative Bacterial Infections; Humans; Infant, Newborn; Infant, Premature; Intensive Care, Neonatal; Male | 2003 |
Intratumoral abscess: an unusual complication of ventriculoperitoneal shunt infection.
Topics: Amikacin; Brain Abscess; Cefotaxime; Cerebellar Neoplasms; Child, Preschool; Combined Modality Therapy; Cranial Fossa, Posterior; Cranial Irradiation; Drug Therapy, Combination; Ependymoma; Gram-Negative Bacterial Infections; Humans; Hydrocephalus; Male; Neoplasm, Residual; Postoperative Complications; Prosthesis-Related Infections; Radiotherapy, Adjuvant; Skull Base Neoplasms; Ventriculoperitoneal Shunt | 2004 |
Comparison of amikacin pharmacokinetics in a killer whale (Orcinus orca) and a beluga whale (Delphinapterus leucas).
Topics: Amikacin; Animals; Anti-Bacterial Agents; Dolphins; Dose-Response Relationship, Drug; Female; Gram-Negative Bacterial Infections; Half-Life; Injections, Intramuscular; Metabolic Clearance Rate; Microbial Sensitivity Tests; Treatment Outcome; Whales | 2004 |
Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres.
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Ceftazidime; Child; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, Pediatric; Humans; Imipenem; Italy; Neoplasms; Retrospective Studies | 2005 |
Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. in Korea: 2003 KONSAR surveillance.
Topics: Acinetobacter; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus faecium; Fluoroquinolones; Gammaproteobacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Korea; Microbial Sensitivity Tests; Population Surveillance; Vancomycin; Vancomycin Resistance | 2006 |
Chromobacterium violaceum: a case report of an unusual bacterium causing puerperal sepsis.
Topics: Academic Medical Centers; Adult; Amikacin; Anti-Bacterial Agents; Chromobacterium; Female; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; India; Puerperal Infection; Sepsis | 2006 |
Primary bacteraemia caused by Rhizobium radiobacter in a patient with solid tumours.
Topics: Adult; Agrobacterium tumefaciens; Amikacin; Anti-Bacterial Agents; Antineoplastic Agents; Bacteremia; Bone Neoplasms; Gram-Negative Bacterial Infections; Humans; Hydroxycorticosteroids; Male; Molecular Sequence Data; Osteosarcoma; Piperacillin; Polymerase Chain Reaction; RNA, Bacterial; RNA, Ribosomal, 16S | 2006 |
Carbapenem-resistant Acinetobacter baumannii: an emerging threat for patients with post-neurosurgical meningitis.
Topics: Acinetobacter baumannii; Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Carbapenems; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meningitis, Bacterial; Meropenem; Microbial Sensitivity Tests; Middle Aged; Neurosurgical Procedures; Postoperative Complications; Thienamycins; Turkey | 2007 |
Stenotrophomonas maltophilia infection of the central venous catheter and lysis of an old thrombosis in a post-bone marrow transplantation child: implications in the fibrinolytic process.
Topics: Amikacin; Bacteriolysis; Bone Marrow Transplantation; Catheterization, Central Venous; Child; Ciprofloxacin; Drug Therapy, Combination; Female; Fibrinolysin; Gram-Negative Bacterial Infections; Humans; Jugular Veins; Stenotrophomonas maltophilia; Transplantation, Homologous; Trimethoprim, Sulfamethoxazole Drug Combination; Venous Thrombosis | 2007 |
[Sepsis caused by pigmented and no pigmented Chromobacterium violaceum].
Topics: Amikacin; Anti-Bacterial Agents; Chromobacterium; Fatal Outcome; Gram-Negative Bacterial Infections; Humans; Imipenem; Indians, South American; Infant; Male; Psoas Abscess; Sepsis | 2007 |
Experience of Comamonas acidovorans keratitis with delayed onset and treatment response in immunocompromised cornea.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Corneal Ulcer; Delftia acidovorans; Drug Therapy, Combination; Eye Infections, Bacterial; Gram-Negative Bacterial Infections; Humans; Immunocompromised Host; Male; Microbial Sensitivity Tests; Middle Aged | 2008 |
Impact of aminoglycoside cycling in six tertiary intensive care units: prospective longitudinal interventional study.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Cost-Benefit Analysis; Croatia; Drug Resistance, Multiple, Bacterial; Gentamicins; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Longitudinal Studies; Netilmicin; Prospective Studies; Sepsis | 2008 |
An 8-year study of resistance to amikacin in gram-negative bacilli isolates from patients with nosocomial infection at one hospital in Argentina.
Topics: Acinetobacter; Amikacin; Argentina; Cross Infection; DNA, Bacterial; Drug Resistance, Microbial; Enterobacteriaceae; Gentamicins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; R Factors | 1995 |
In vitro stepwise selection of resistance to quinolones, beta-lactams and amikacin in nosocomial gram-negative bacilli.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Evaluation Studies as Topic; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Infection Control; Risk Factors | 1994 |
[Adaptive control of therapeutics using amikacin in very old patients: retrospective analysis of efficacy and toxicity].
Topics: Aged; Aged, 80 and over; Amikacin; Creatinine; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Male; Retrospective Studies | 1994 |
Catheter-associated sepsis due to Alcaligenes xylosoxidans in a child with AIDS.
Topics: AIDS-Related Opportunistic Infections; Alcaligenes; Amikacin; Bacteremia; Catheterization, Central Venous; Ceftazidime; Child; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacterial Infections; Humans; Male | 1993 |
Pharmacokinetics of once-daily amikacin in elderly patients.
Topics: Aged; Aged, 80 and over; Amikacin; Drug Administration Schedule; Female; Gram-Negative Bacterial Infections; Half-Life; Humans; Male; Metabolic Clearance Rate | 1993 |
Aminoglycoside volume of distribution and illness severity in critically ill septic patients.
Topics: Adult; Amikacin; Creatinine; Critical Illness; Extracellular Space; Gram-Negative Bacterial Infections; Humans; Sepsis; Severity of Illness Index | 1993 |
[Bacteremia caused by Capnocytophaga sp: presentation of 2 cases, one with endocarditis. Review of the literature].
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Bacteremia; Capnocytophaga; Cefotaxime; Ceftazidime; Cephalosporins; Endocarditis, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Male | 1996 |
Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Resistance, Microbial; Enterobacter; Gram-Negative Aerobic Bacteria; Gram-Negative Bacterial Infections; Hospital Bed Capacity; Hospitals, Teaching; Humans; Imipenem; Intensive Care Units; Klebsiella pneumoniae; Lung; Microbial Sensitivity Tests; Product Surveillance, Postmarketing; Pseudomonas aeruginosa; Risk Factors; Thienamycins; Wounds and Injuries | 1996 |
Efficacy and safety of once-daily amikacin in combination with ceftazidime in critically ill adults with severe gram-negative infections.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; APACHE; Ceftazidime; Critical Illness; Drug Administration Schedule; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged | 1996 |
Fatal myofascial necrosis due to imipenem-resistant Aeromonas hydrophila.
Topics: Adult; Aeromonas hydrophila; Amikacin; Anemia, Aplastic; Anti-Bacterial Agents; Drug Resistance, Microbial; Fatal Outcome; Gram-Negative Bacterial Infections; Humans; Imipenem; Immunocompromised Host; Male; Muscular Diseases; Necrosis; Thienamycins; Thigh | 1997 |
Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
Topics: Adult; Amikacin; Anti-Bacterial Agents; APACHE; Critical Care; Cross-Sectional Studies; Female; Gram-Negative Bacterial Infections; Half-Life; Hemodynamics; Humans; Infusion Pumps; Intensive Care Units; Male; Metabolic Clearance Rate; Middle Aged; Sepsis | 1997 |
Pharmacokinetics of amikacin in intensive care unit patients.
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Critical Care; Diagnosis-Related Groups; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Male; Middle Aged | 1996 |
[Severe diffuse facial cellulitis].
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Bacterial Infections; Cause of Death; Cellulitis; Child; Drug Therapy, Combination; Face; Female; Forecasting; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Male; Metronidazole; Neck; Penicillins; Piperacillin; Premedication; Risk Factors; Treatment Outcome | 1997 |
Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who developed bacteraemia during antimicrobial prophylaxis: a case-control study.
Topics: Amikacin; Amphotericin B; Antibiotic Prophylaxis; Bacteremia; Bacterial Infections; Case-Control Studies; Catheters, Indwelling; Ceftazidime; Drug Therapy, Combination; Enterococcus; Female; Fluconazole; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Male; Neoplasms; Neutropenia; Ofloxacin; Retrospective Studies; Streptococcal Infections; Treatment Outcome; Vancomycin; Xanthomonas | 1998 |
Killing kinetics of intracellular Afipia felis treated with amikacin.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Cell Line; Colony Count, Microbial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Lysosomes; Macrophages; Mice; Phagosomes | 1998 |
Edwardsiella tarda bacteraemia--complicated by acute pancreatitis and pyomyoma.
Topics: Acute Disease; Amikacin; Anti-Bacterial Agents; Bacteremia; Blood Chemical Analysis; Cefoxitin; Cephamycins; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Hysterectomy; Middle Aged; Myoma; Ovariectomy; Pancreatitis; Tomography, X-Ray Computed; Uterus | 1999 |
Prevalent nosocomial gram negative aerobic bacilli and their antimicrobial susceptibility pattern in intensive care unit.
Topics: Amikacin; Anti-Bacterial Agents; Cross Infection; Gram-Negative Bacterial Infections; Humans; Imipenem; Infant, Newborn; Intensive Care Units; Microbial Sensitivity Tests; Prospective Studies; Thienamycins | 1999 |
Treatment of gram-negative bacterial meningitis in term neonates with third generation cephalosporins plus amikacin.
Topics: Amikacin; Anti-Bacterial Agents; Cefotaxime; Ceftazidime; Cephalosporin Resistance; Cephalosporins; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Greece; Humans; Infant, Newborn; Male; Meningitis, Bacterial; Morbidity; Retrospective Studies | 2000 |
[Cost of antibiotic therapy in neutropenic patients undergoing peripheral blood stem cell transplantation for breast cancer].
Topics: Amikacin; Antineoplastic Agents; Breast Neoplasms; Drug Costs; Drug Therapy, Combination; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Hematopoietic Stem Cell Transplantation; Hospital Costs; Humans; Neutropenia; Penicillanic Acid; Piperacillin; Spain; Tazobactam; Teicoplanin; Transplantation Conditioning; Treatment Failure; Treatment Outcome; Vancomycin | 2000 |
Comparative activities of isepamicin, amikacin, cefepime, and ciprofloxacin alone or in combination with other antibiotics against Stenotrophomonas maltophilia.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Cephalosporins; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Gentamicins; Gram-Negative Bacterial Infections; Microbial Sensitivity Tests; Stenotrophomonas maltophilia; Time Factors | 2001 |
Aeromonas sobria sepsis in a neutropenic patient.
Topics: Acute Disease; Aeromonas; Aged; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Female; Gram-Negative Bacterial Infections; Humans; Leukemia, Myeloid; Neutropenia; Sepsis | 2001 |
Ceftazidime and amikacin as empiric treatment of febrile episodes in neutropenic patients in Saudi Arabia.
Topics: Adult; Amikacin; Ceftazidime; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Hospitals, University; Humans; Mycoses; Neoplasms; Neutropenia; Saudi Arabia; Sepsis; Treatment Outcome | 1992 |
A 56-month prospective surveillance study on the epidemiology of aminoglycoside resistance in a Belgian general hospital.
Topics: Amikacin; Anti-Bacterial Agents; Belgium; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Prospective Studies | 1992 |
Increased resistance to amikacin in a neonatal unit following intensive amikacin usage.
Topics: Amikacin; Anti-Bacterial Agents; Drug Resistance, Microbial; Drug Utilization; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospital Departments; Humans; Infant; Infant, Newborn; Intensive Care Units, Neonatal; Microbial Sensitivity Tests; Pediatrics; South Africa | 1992 |
[In vitro activity of various antibiotic agents against gram-negative nosocomial bacteremia pathogens].
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Cross Infection; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Ofloxacin | 1992 |
Alterations in the microbial flora and in the incidence of bacteremia at a university hospital after adoption of amikacin as the sole formulary aminoglycoside.
Topics: Amikacin; Bacteremia; Drug Resistance, Microbial; Gentamicins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Incidence; Louisiana; Prospective Studies; Tobramycin | 1992 |
Individualizing amikacin regimens: accurate method to achieve therapeutic concentrations.
Topics: Adult; Aged; Aging; Amikacin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genetic Variation; Gram-Negative Bacterial Infections; Humans; Kidney; Male; Middle Aged; Models, Biological | 1991 |
New epidemiological data on resistance to netilmicin and other aminoglycosides.
Topics: Amikacin; Anti-Bacterial Agents; Drug Resistance, Microbial; Enterobacteriaceae; Gentamicins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Netilmicin; Pseudomonas aeruginosa; Tobramycin | 1991 |